HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Long-term survival of patients treated with octreotide for metastatic well differentiated neuroendocrine carcinoma of the lung.

Abstract
Two patients with a radically operated well differentiated neuroendocrine carcinoma (WDNC) of the lung who developed a carcinoid syndrome due to metastatic spread of the tumor are reported. Treatment with somatostatin analogue octreotide was administered to both patients following their refusal of a standard chemotherapic regimen. Prompt resolution of the carcinoid syndrome was observed in both following octreotide treatment and both patients are alive and well after more than four years without evidence of further progression of the tumor. It is suggested that octreotide should be considered as an effective therapy in WDNC for the control of the disease and associated paraneoplastic syndromes.
AuthorsP L Filosso, S Croce, A Oliaro, E Ruffini
JournalThe Journal of cardiovascular surgery (J Cardiovasc Surg (Torino)) Vol. 41 Issue 5 Pg. 773-6 (Oct 2000) ISSN: 0021-9509 [Print] Italy
PMID11149647 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antineoplastic Agents, Hormonal
  • Octreotide
Topics
  • Antineoplastic Agents, Hormonal (therapeutic use)
  • Carcinoma, Neuroendocrine (drug therapy, mortality, pathology, secondary)
  • Humans
  • Lung Neoplasms (drug therapy, mortality, pathology, secondary)
  • Male
  • Middle Aged
  • Octreotide (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: